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Abstract
Background: Fibroblast growth factor receptor 4 (FGFR4) is a member of a receptor tyrosine kinase family of enzymes
involved in cell cycle control and proliferation. A common single nucleotide polymorphism (SNP) Gly388Arg variant has
been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue
sarcomas. The present study evaluated the prognostic significance of FGFR4 in oral and oropharynx carcinomas, finding an
association of FGFR4 expression and Gly388Arg genotype with tumor onset and prognosis.
Patients and Methods: DNA from peripheral blood of 122 patients with oral and oropharyngeal squamous cell carcinomas
was used to determine FGFR4 genotype by PCR-RFLP. Protein expression was assessed by immunohistochemistry (IHC) on
paraffin-embedded tissue microarrays.
Results: Presence of allele Arg388 was associated with lymphatic embolization and with disease related premature death. In
addition, FGFR4 low expression was related with lymph node positivity and premature relapse of disease, as well as disease
related death.
Conclusion: Our results propose FGFR4 profile, measured by the Gly388Arg genotype and expression, as a novel marker of
prognosis in squamous cell carcinoma of the mouth and oropharynx.
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Introduction
The fibroblast growth factor receptor (FGFRs) family comprises
structurally related tyrosine kinase receptors (FGFR1-4) involved
in signaling via interactions with fibroblast growth factors (FGFs),
playing an important role in a wide range of biological processes,
including differentiation, proliferation, cell motility and angiogen-
esis [1,2]. Most FGFs have mitogenic activity in a variety of
systems, including cell growth, differentiation and migration [1].
The proliferative capacity of FGFs is a function of FGFRs, to
which they bind and through which they signal.
Deregulation in FGF/FGFR signaling has been implicated in
human malignant diseases [3–6]. Functional studies demonstrated
that FGFR4 interferes in signaling events leading to normal cell
adhesiveness and corresponding invasive properties of pituitary
tumors [7]. Although the molecular basis of this function is still a
matter of intense research, FGFR4 seems to play a role in a
broader range of human cancers [7–9].
A single nucleotide polymorphism (SNP) in exon 9 results in an
amino acid change (substitution of a glycine residue for an arginine
- Gly388Arg) within FGFR4 transmembrane domain and a
positive correlation with prognostic parameters in several human
cancers, including breast, colon, lung, prostate and head and neck
cancers [7,9–14]. Nevertheless, the association between the
Gly388Arg genotype and cancer prognosis is not yet clear [15–
18], especially in head and neck squamous cell carcinomas
(HNSCC).
HNSCC ranks among the top ten most common cancers
worldwide, with a large incidence variation according to sex and
geographical location [19]. No biomarkers are currently available
for HNSCC patients; prognosis depends largely on the stage at
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presentation, with the most important prognostic factor being the
presence of neck node metastases [20].
To our knowledge, there is a lack of studies suggesting the
prognostic significance of FGFR4 SNP genotype in HNSCC
[9,12]. Streit et al [9] evaluated 104 paraffin-embedded tumors
and concluded that high expression of FGFR4 together with the
Arg388 allele is associated with poor clinical outcome. In
comparison, da Costa Andrade et al [12] presented results
claiming an association between the FGFR4 Arg388 allele and
shortened survival in 75 HNSCC patients. Given the small
number of patients with tumors of different primary sites evaluated
in these studies and the controversial involvement of FGFR family
in human cancers, we decided to further investigate the impact the
Gly388Arg polymorphism in HNSCC.
The present study evaluated the prognostic significance of
FGFR4 expression and the Gly388Arg genotype in oral and
oropharynx carcinomas in regard to tumor onset and prognosis.
Possible correlations with clinicopathological and prognosis
parameters were also analyzed.
Materials and Methods
Ethics
This study was approved by the Committee of Ethics in
Research of the Heliopolis Hospital on 07/12/2005 (CEP # 402)
and an informed consent was obtained from all patients enrolled.
Samples
Samples were collected by the Head and Neck Genome Project
(GENCAPO), a collaborative consortium created in 2002 with
more than 50 researchers from 9 institutions in Sa˜o Paulo State,
Brazil, whose aim is to develop clinical, genetic and epidemiolog-
ical analysis of HNSCC. In this study, 122 DNA and 75 tumoral
tissue samples were obtained and used for polymorphism
Gly388Arg genotyping and immunohistochemical analysis of the
FGFR4 gene, respectively, within a total of 125 patients with oral
and oropharyngeal squamous cell carcinomas, surgically treated at
the Head and Neck Surgery Department of Helio´polis Hospital
and Arnaldo Vieira de Carvalho Caˆncer Hospital, Sa˜o Paulo,
Brazil, during the period of January/2002 to December/2007.
The clinical follow-up was at least 48 months after surgery.
Previous surgical treatment, distant metastasis, no removal of
cervical lymph nodes and positive surgical margins were exclusion
criteria. Histopathological slides were reviewed by a senior
pathologists to confirm the diagnosis and select appropriate areas
for Immunohistochemical analysis. Tumors were classified ac-
cording to the TNM system [21]. Clinical, epidemiological and
pathological characteristics of tumors are described in Table 1.
Genotyping
Genomic DNA was extracted from peripheral blood samples of
122 patients as previously described [22]. Genotypes were
determined by polymerase chain reaction restriction fragment
length polymorphism (PCR-RFLP). FGFR4 exon 9 was amplified
using primers described by Bange et al, [8] and analyzed for
Gly388Arg polimorfism (rs351855). Selected primers were 59 -
GAC CGC AGC AGC GCC CGA GGC CAG - 39 and 59 - AGA
GGG AAG AGG GAG AGC TTC TG - 39 (Life Technologies,
IncH, Sa˜o Paulo, SP, Brazil), which produce a 168-base pair (bp)
fragment. PCR conditions were: a 25-mL reaction mixture
containing 200 ng of genomic DNA, 10 mM Tris-HCl (pH 8.3),
50 mM KCl, 200 mM of each deoxyribonucleoside 59 triphos-
phates, 1.5 mM de MgCl2, 1 U Taq DNA polimerase (Life
Technologies, IncH, Rockville, MD, USA) and 25 pmol of each
primer. PCR initiated with a melting step of 5 minutes at 94uC,
followed by 35 cycles of 1 minute at 94uC, 1 minute at 58uC and 1
minute at 72uC. PCR products were digested overnight with BstNI
following the manufacturer’s instructions (New England BiolabsH,
Berverly, MA, USA). Restriction fragments were resolved on a
12% non-denaturing polyacrylamide gel. SNP Arg388 in FGFR4
gene was characterized by two distinctive fragments of 82 and
27 bp, whereas the FGFR4 Gly388 wild-type allele was identified
by a single fragments of 109bp.
Tissue Microarray
Tissue microarrays were made using buffered formalin-fixed
paraffin-embedded tissue sections from 75 primary oral and
oropharyngeal squamous cell carcinomas treated at the Head and
Neck Surgery Department of Helio´polis Hospital, Sa˜o Paulo, SP,
were used for immunohistochemistry (IHC) analysis. Histological
characterization of all samples was done by Hematoxylin and
Eosin staining, followed by immunohistochemistry analysis of
tissue microarrays (TMA). Two 1 mm cylinders were used to
represent each sample in the TMA slide (Beecher InstrumentsH,
Silver Spring, MD, USA).
Immunohistochemistry
Anti-FGFR4 monoclonal antibody (Santa Cruz Biotechnolo-
gyH, USA) was used in the IHC reaction, at a 1:400 dilution [23–
25]. Positive (lung control) and negative controls (absence of
primary or secondary antibody) were used for reaction quality
control. Sample scoring was performed by semi-quantitative
microscopic analysis, considering the number of stained tumor
cells and signal intensity. Two spots were evaluated for each
sample and a mean score was calculated. Considering the
percentage of FGFR4 immune-positive tumor cells, a score of 1
was given when #10% of cells were positive; 2 when 10–50% and
3 when $50% of cells were positive. Signal intensity was scored as
negative (0), weak (1), moderate (2) and strong (3). Both scores
were multiplied [26,27] and the resulting score was used to
categorize FGFR4 expression as negative (#3), low (.3 and ,7)
and high (.7).
Statistical Analysis
The chi square and Fisher exact tests were used for association
analysis and confirmation was obtained by the Lilliefors test
(significance considered when p,0.05). Multivariate logistic
regression was used to obtain odds ratio (OR) and confidence
intervals (CI$95%). Survival was calculated by the number of
months between surgery and death for each patient or the last
appointment in case the patient was alive. In order to calculate
disease-free survival, the time endpoint was the date of disease
relapse. The Kaplan-Meier model was used for survival analysis,
using the Wilcoxon p-value and the Cox Proportional Hazards to
adjust p-values and obtain hazard ratio (HR). Statistical calcula-
tions were performed using the Epi InfoH v3.4.3, 2007 and Statsoft
StatisticaH v7.0.61.0 softwares. Genotype correlation with certain
biological variables such as age and gender were not analyzed
because we could not find biological justifications for these
analyses.
Results
FGFR4 Gly388Arg Genotype
Regarding the SNP Gly388Arg, 66 (54.1%) cases were
genotyped as Gly/Gly (wild type allele), 47 (38.5%) as Gly/Arg
and 26 (7.4%) as Arg/Arg. Allele and genotype frequencies were
in Hardy-Weinberg equilibrium.
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Table 1. Epidemiological, clinical and pathological tumor features and their association with Gly388Arg polymorphism and FGFR4
expression.
Epidemiological, clinical
and pathological features FGFR4
Genotype Gly388Arg Expression level
Total
Gly/
Gly
Gly/Arg
+Arg/Arg
P
value Total Low High
P
value
No. (%) No. (%)
Gender
Male 106 (86.9) – – – 62 (82.7) – – –
Female 16 (13.1) – – – 13 (17.3) – – –
Age, yr
median 54, df 610.2
Smoker 98 (80.3) – – – 54 (72.0) – – –
Alcoholic 74 (60.7) – – – 42 (56.0) – – –
Treatment
Only operated 43 (35.2) – – – 34 (45.3) – – –
Operated+irradiated 79 (64.8) – – – 41 (54.7) – – –
Tumor sities
Oral cavity 87 (71.3) – – – 60 (80.0) – – –
Oropharynx 35 (28.7) – – – 15 (20.0) – – –
Tumor size (T)
T1+T2 48 (39.3) 26 22 0.993 29 (38.7) 18 11 0.051
T3 31 (25.4) 17 14 19 (25.3) 9 10
T4 43 (35.3) 23 20 27 (36.0) 22 5
Lymph nodes
Absent 59 (48.4) 35 24 0.262 31 (41.3) 16 15 0.036
Present 63 (51.6) 31 32 44 (58.7) 33 11
Differentiation
Well 47 (38.5) 24 23 0.700 32 (42.7) 24 8 0.062
Moderately 65 (53.3) 37 28 35 (46.7) 18 17
Poorly 9 (7.4) 4 5 7 (9.3) 6 1
Not available a 1 (0.8) 1 (1.3)
Lymphatic embolization
Negative 54 (44.3) 35 19 0.022 26 (34.7) 21 5 0.034
Positive 66 (54.1) 29 37 49 (65.3) 28 21
Not available a 2 (1.6) 0 (0.0)
Perineural invasion
Negative 63 (51.6) 31 32 0.386 39 (52.0) 24 15 0.526
Positive 56 (45.9) 32 24 35 (46.7) 24 11
Not available a 3 (2.5) 1 (1.3)
Disease specific death
No 55 (45.1) 37 18 0.008 40 (53.3) 21 19 0.013
Yes 44 (36.0) 18 26 31 (41.4) 25 6
Not available a 23 (18.9) 4 (5.3)
Disease relapse
No 44 (36.1) 29 15 0.110 33 (44.0) 17 16 0.037
Yes 56 (45.9) 28 28 40 (53.3) 30 10
Not available a 22 (18.0) 2 (2.7)
Total 122 (100.0) 66 56 75 (100.0) 49 26
aNot available (not considered in the statistical calculations).
doi:10.1371/journal.pone.0050747.t001
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The Gly388Arg polymorphism did not show a significant
association with tumor size (p = 0.993), positive lymph nodes
(p = 0.262) and differentiation grade (p = 0.700), but was signifi-
cantly associated with lymphatic embolization (p = 0.022, Table 1).
Multivariate analysis showed that presence of at least one allele
Arg388 is an independent marker for lymphatic embolization
(OR = 3.88, CI = 1.14–13.13, Table 2).
The Gly388Arg polymorphism was significantly associated with
disease specific death (p = 0.008, Table 1) and multivariate analysis
showed that presence of Arg388 allele is an independent death risk
factor, increasing risk 6 times when compared to absence of this
allele (OR = 6.88, CI = 1.64–28.87, Table 2). Nevertheless, the
Gly388Arg polymorphism was not correlated with disease relapse
(p = 0.110, Table 1).
Although disease-free survival did not show a significant
association with FGFR4 polymorphisms (p = 0.130), presence of
the Arg388 allele was associated with disease specific survival
(p = 0.020). According to a 36 month after surgery follow up,
approximately 25% of cases with the Gly/Gly genotype died of
disease specific causes, as compared to approximately 55% of
deaths in patients with the Arg388 allele (Figure 1b). Multivariate
analysis revealed that the presence of Arg388 allele is an
independent marker of disease specific death, with a 3 fold
increased risk when compared with absence of this allele
(HR = 3.26, CI = 1.40–7.58, Table 3).
FGFR4 Expression
FGFR4 expression was detected in 75 tumors, being classified as
high in 26 (34.7%) samples and low in 49 (65.3%) (Figure 2a and
2b, respectively. No samples were negative for FGFR4 expression.
FGFR4 expression did not show a significant association with
tumor characteristics such as size (p = 0.051) and differentiation
grade (p = 0.062), but was significantly associated with positive
lymph nodes (p = 0.036, Table 1). Multivariate analysis showed
that low FGFR4 expression is an independent marker for lymph
node positivity (OR = 3.81, CI = 1.12–12.98, Table 2). FGFR4
expression did significantly correlate with disease relapse
(p = 0.037) and disease specific death (p = 0.013, Table 1).
Multivariate analysis showed that FGFR4 low expression is an
independent marker of disease relapse and disease specific death,
representing an increased risk of over 6 times for both, in relation
to high expression (respectively, OR = 6.73, CI = 1.63–27.85 and
OR = 6.86, CI = 1.45–32.40, Table 2).
Disease-free and disease specific survival were significantly
correlated with FGFR4 expression (p = 0.044 and p = 0.034,
respectively). According to a 24 month after surgery follow up,
approximately 60% of cases with low expression died of disease
specific causes, as compared to approximately 30% of deaths in
patients with high expression of FGFR4 (Figure 1c). Additionally,
according to a 36 month after surgery follow up, approximately
50% of cases with low expression presented disease relapse, as
compared to approximately 20% of recurrence in patients with
Table 2. Multivariate analysis of the relationship between clinical and pathological tumor features with gene polymorphism and
FGFR4 expression.
Variables Multivariate analysis
Lymphatic embolization Lymph-nodes Disease relapse Disease specific death
OR (95% CI) a P value b OR (95% CI) a P value b OR (95% CI) a P value b OR (95% CI) a P value b
FGFR4 expression
High 1 1 1 1
Low 0.46 (0.13–1.68) 0.245 3.81 (1.12–12.98) 0.032 6.73 (1.63–27.85) 0.009 6.86 (1.45–32.40) 0.015
FGFR4 genotype Gly388Arg
Gly/Gly 1 1 1 1
Gly/Arg+Arg/Arg 3.88 (1.14–13.13) 0.029 1.88 (0.60–5.83) 0.276 3.57 (0.99–12.91) 0.052 6.88 (1.64–28.87) 0.008
Tumor size (T)
T1+T2 1 1 1 1
T3 2.00 (0.45–8.84) 0.358 1.38 (0.36–5.22) 0.640 3.13 (0.67–14.57) 0.147 2.67 (0.52–13.78) 0.241
T4 1.12 (0.30–4.23) 0.859 3.16 (0.86–11.59) 0.083 1.11 (0.28–4.33) 0.885 2.31 (0.57–9.39) 0.242
Differentiation
Well 1 1 – – – –
Moderately 2.77 (0.83–9.18) 0.094 2.98 (0.90–9.88) 0.075 – – – –
Poorly 5.70 (0.47–69.08) 0.171 3.91 (0.35–43.15) 0.266 – – – –
Lymph nodes
Absent – – – – 1 1
Present – – – – 7.69 (1.21–49.00) 0.031 9.44 (1.52–58.65) 0.016
Irradiated
No – – – – 1 1
Yes – – – – 0.07 (0.01–0.50) 0.008 0.39 (0.07–2.18) 0.286
a, bValues adjusted by multivariate logistic regression.
For Gly388Arg and FGFR4 expression correlation with lymphatic embolization and lymph node status, tumor size and differentiation status were considered in the
multivariate analysis. For disease relapse and disease specific death, tumor size, lymph node status and radiotherapy treatment were considered.
doi:10.1371/journal.pone.0050747.t002
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high expression of FGFR4 (Figure 1d). Multivariate analysis
revealed that a low expression of FGFR4 is an independent
marker for a faster disease relapse and disease specific death, with
a 3 fold increased risk when compared to high expression
(respectively, HR = 3.26, CI = 1.44–7.37 and HR = 3.26,
CI = 1.21–8.74, Table 3).
Figure 1. Survival plots. a. and b.: Disease-free survival and disease specific survival according to FGFR4 Gly388Arg polymorphism; c. and d.:
Disease-free survival and disease specific survival according to FGFR4 expression; e. and f.: Disease-free survival and disease specific survival according
to FGFR4 profile.
doi:10.1371/journal.pone.0050747.g001
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FGFR4 Risk Profiles
In an attempt to combine genotype and expression results, we
categorized the FGFR4 profile in three classes: low risk (high
expression and absence of Arg388 allele); intermediate risk (high
expression and presence of Arg388 allele or low expression and
absence of Arg388 allele) and high risk (low expression and
presence of Arg388 allele). Frequencies of each FGFR4 profile
were 11 (15.5%), 43 (60.6%) and 17 (23.9%), respectively for low,
intermediate and high risk.
Disease-free and disease specific survival were significantly
correlated with FGFR4 profiles (p = 0.002 and p,0.001, respec-
tively). According to a 24 month after surgery follow up, all cases
classified as high risk had relapsed and approximately 80% died of
disease specific causes, as compared to approximately 30% of
recurrence and no deaths of patients classified as low risk (Figure 1e
and 1f). Multivariate analysis revealed that the high risk category is
an independent marker for a faster disease relapse and disease
specific death, with a 4.5 and 13 fold increased risk, respectively,
when compared to the low risk profile (HR = 4.50, CI = 1.37–
14.82 and HR = 12.90, CI = 1.54–107.69).
Discussion and Conclusions
FGFR4 belongs to the family of fibroblast growth factor
receptors (FGFR1-4), transmembrane proteins with tyrosine
kinase activity. Multiple signal transduction cascades are initiated
after binding of FGF ligand to the extracellular domain of the
receptor, ultimately resulting in gene expression changes [1,2].
FGFRs have been shown to play important roles in several
processes of embryonic development and tissue homeostasis. Their
abnormal expression or mutation can cause diverse pathologies,
ranging from morphogenetic disorders to cancer [28]. This is a
group of proteins of considerable interest in cancer biology,
because they regulate essential processes, including mitogenic and
angiogenic activity, having important roles in cell differentiation,
development, proliferative signaling and motility [2,29,30].
Several studies have examined the role of FGFR4 in carcino-
genesis, providing evidences for the complexity of FGF/FGFR
signaling pathways in different tumor types [7,31–33].
Although the presence of FGFR4 Arg388 allele has been shown
to indicate a poor prognosis in several tumors [8,10,11,34], the
mechanism by which it affects cancer progression remains unclear.
This might be related to signaling cascades that control cell-matrix
adhesion and angiogenesis [35].
Although some mechanisms have been described in the
literature, the influence of Gly388Arg polymorphism in tumor
aggressiveness may differ in specific tumors.
Our study revealed that low FGFR4 expression in the presence
of Arg388 allele is associated with worse survival in patients with
oral and oropharyngeal squamous cell carcinoma.
Seitzer, et al, [36] verified, using an animal model, that low
protein expression, even in the presence of FGFR4 Arg388
polymorphism, is related to increased pathway activity. This may
be explained by the activation of alternative proteins in the
signaling cascade or other cascades.
Recently, it has been reported that the presence of polymor-
phism Gly388Arg is associated with increased cancer risk and
progression of pituitary tumors through recruitment of STAT3
signaling cascade. Activation of this cascade can result in
deregulation of cell proliferation and apoptosis, leading to tumor
progression [37]. Signaling hiperactivation by specific mutations
depends on their resistance to negative feedback loops [38]. In
addition, several ubiquitylation proteins bind directly to RTKs
altering receptor activation [39]. RTK Ubiquitylation may
promote receptor degradation creating an important negative
feedback mechanism [40,41].
Table 3. Multivariate analysis of disease specific survival.
Variables Cox proportional
Disease-free survival Disease-specific survival
HR (95% CI) a P value b HR (95% CI) a P value b
FGFR4 expression
High 1 1
Low 3.26 (1.44–7.37) 0.005 3.26 (1.21–8.74) 0.019
FGFR4 genotype Gly388Arg
Gly/Gly 1 1
Gly/Arg+Arg/Arg 1.77 (0.85–3.67) 0.124 3.26 (1.40–7.58) 0.006
Tumor size (T)
T1+T2 1 1
T3 3.53 (1.46–8.52) 0.005 3.35 (1.13–9.92) 0.029
T4 1.99 (0.85–4.69) 0.115 1.65 (0.64–4.26) 0.304
Lymph nodes
Absent 1 1
Present 2.62 (1.05–6.53) 0.039 4.80 (1.56–14.73) 0.006
Irradiated
No 1 1
Yes 0.22 (0.09–6.53) 0.002 0.48 (0.18–1.27) 0.139
a, bValues adjusted by Cox proportional hazards.
Tumor size, lymp node status and radiotherapy treatment were considered in the multivariate analysis.
doi:10.1371/journal.pone.0050747.t003
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FGFR4 Arg388 has not been consider an oncogene per se, but
rather collaborate with oncogenes involved in cell motility and
invasiveness [36].
Our findings may have important therapeutic implications,
because inhibition of one intracellular pathway may lead to
activation of parallel signaling pathways, thereby decreasing the
effectiveness of single-agent targeted therapies [42]. In support of
our hypothesis, the Arg388 allele was associated with resistance to
adjuvant therapy in breast cancer [43].
Ansell et al, [44], were the first researchers to report that the
Gly388 allele showed a significantly higher risk of developing
Figure 2. Immunohistochemical analysis of tumors. (a) strong FGFR4 expression; (b) weak FGFR4 expression. Magnification was 4006.
doi:10.1371/journal.pone.0050747.g002
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cancer, proposing the Gly388 allele as a risk allele for head and
neck cancer.
In contrast, Streit et al, [9] reported that in head and neck SCC,
expression of Gly388 FGFR4 had no impact on disease
progression. In another study, da Costa Andrade et al, [12]
observed that the presence of at least one Arg allele was
significantly correlated with reduced overall survival and an
increased mortality risk of 2.2. In a recent study, Tanuma et al,
[35] reported that FGFR4 Arg388 allele was strongly associated
with poor prognosis.
In the present study, we have shown that allele Arg388 is
associated with lymphatic embolization and premature disease
related death. Furthermore, low expression of FGFR4 is related to
lymph node positivity and premature disease relapse and death in
patients with SCC of the mouth and oropharynx.
Based on these results, we have classified patients with low
FGFR4 expression/Arg388 as high risk for relapse and death. In
contrast, high FGFR4 expression/Arg388-negative patients were
considered at low risk. In conclusion, we propose FGFR4 profile as
a novel prognostic marker in SCC of the mouth and oropharynx.
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